2 weeks Ago By ABMN Staff
Vera Therapeutics, Inc. ( NASDAQ:VERA – Get Free Report )’s stock price was down 5.8% during mid-day trading on Friday following insider selling activity.
The stock traded as low as $43.03 and last traded at $43.03.
Approximately 376,845 shares traded hands during trading, a decline of 59% from the average daily volume of 910,906 shares. The stock had previously closed at $45.66.
Specifically, CEO Marshall Fordyce sold 23,125 shares of the company’s stock in a transaction that occurred on Wednesday, September 25th. The stock was sold at an average price of $46.05, for a total value of $1,064,906.
25. Following the completion of the sale, the chief executive officer now owns 307,972 shares of the company’s stock, valued at $14,182,110.60.
The sale was disclosed in a legal filing with the SEC, which can be accessed through this link . Wall Street Analyst Weigh In Several research analysts have commented on the stock. Cantor Fitzgerald reissued an “overweight” rating and set a $107.
00 price target on shares of Vera Therapeutics in a research note on Monday, September 23rd. JPMorgan Chase & Co. increased their target price on shares of Vera Therapeutics from $62.
00 to $72.00 and gave the company an “overweight” rating in a report on Tuesday, September 3rd. Finally, Evercore ISI raised shares of Vera Therapeutics to a “strong-buy” rating in a research note on Monday, September 16th.
One equities research analyst has rated the stock with a hold rating, six have given a buy rating and two have issued a strong buy rating to the company. According to MarketBeat.com, the stock presently has an average rating of “Buy” and a consensus price target of $51.
75. Vera Therapeutics Price Performance The company has a debt-to-equity ratio of 0.15, a current ratio of 21.
43 and a quick ratio of 21.43. The firm has a market capitalization of $2.
38 billion, a P/E ratio of -21.19 and a beta of 0.99.
The firm’s 50 day simple moving average is $38.40 and its two-hundred day simple moving average is $39.07.
Vera Therapeutics ( NASDAQ:VERA – Get Free Report ) last issued its quarterly earnings data on Thursday, August 8th. The company reported ($0.62) EPS for the quarter, missing the consensus estimate of ($0.
56) by ($0.06). As a group, analysts predict that Vera Therapeutics, Inc.
will post -2.57 earnings per share for the current year. Hedge Funds Weigh In On Vera Therapeutics Several hedge funds and other institutional investors have recently modified their holdings of VERA.
Crestline Management LP raised its stake in shares of Vera Therapeutics by 32.4% during the fourth quarter. Crestline Management LP now owns 60,069 shares of the company’s stock valued at $924,000 after acquiring an additional 14,689 shares during the last quarter.
Rafferty Asset Management LLC raised its stake in shares of Vera Therapeutics by 25.2% during the fourth quarter. Rafferty Asset Management LLC now owns 170,758 shares of the company’s stock valued at $2,626,000 after acquiring an additional 34,381 shares during the last quarter.
Schroder Investment Management Group bought a new position in shares of Vera Therapeutics during the fourth quarter valued at about $17,087,000. Pale Fire Capital SE bought a new position in shares of Vera Therapeutics during the fourth quarter valued at about $252,000. Finally, Kynam Capital Management LP raised its stake in shares of Vera Therapeutics by 23.
5% during the fourth quarter. Kynam Capital Management LP now owns 3,650,339 shares of the company’s stock valued at $56,142,000 after acquiring an additional 694,286 shares during the last quarter. 99.
21% of the stock is owned by institutional investors. Vera Therapeutics Company Profile ( Get Free Report ) Vera Therapeutics, Inc, a clinical stage biotechnology company, focuses on developing and commercializing treatments for patients with serious immunological diseases. Its lead product candidate is atacicept, a fusion protein self-administered as a subcutaneous injection that is in Phase III clinical trial for patients with immunoglobulin A nephropathy; and for treatment of lupus nephritis that is in Phase II clinical trial.
Recommended Stories Receive News & Ratings for Vera Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Vera Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter ..
